Aliabadi Parastoo Karimi, Sohrab Mehrnoush, Hessami Amirhossein, Afshari Mahdi, Kashi Zahra, Kheradmand Motahareh, Hedayatizadeh-Omran Akbar, Alizadeh-Navaei Reza, Moosazadeh Mahmood
Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Ir J Med Sci. 2022 Jun;191(3):1201-1208. doi: 10.1007/s11845-021-02694-0. Epub 2021 Jun 25.
The association between liver enzymes and metabolic syndrome (MetS) has been evaluated in several studies with different results. The purpose of this study is to determine the association between the serum levels of these liver enzymes and MetS in Tabari cohort population.
In this case-control study, data collected from the enrolment phase of the Tabari cohort population have been used. MetS was defined based on IDF (international diabetes federation) standards. Then, 476 patients with MetS (case group) and 476 age-sex matched controls were selected randomly.
Mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were higher in case group than control group (20.59 vs. 19.99 respectively, p = 0.339 and 24.64 vs. 20.16 respectively, p < 0.001). The chance of having MetS, high triglyceride, and fasting blood glucose (FBG) was significantly higher in people with ALT ≥ 40 (1.63, 2.35, and 2.02, respectively). The chance of having MetS in people with AST ≥ 40 was 1.45 times higher than that among those with normal AST level (p > 0.05).
This study showed that there is an association between liver enzymes and MetS as well as some of its components. Liver enzymes, especially ALT, can be used as an early indicator of MetS in the at risk population.
多项研究对肝酶与代谢综合征（MetS）之间的关联进行了评估，结果各异。本研究旨在确定塔巴里队列人群中这些肝酶的血清水平与MetS之间的关联。
在这项病例对照研究中，使用了从塔巴里队列人群入组阶段收集的数据。MetS根据国际糖尿病联盟（IDF）标准定义。然后，随机选择了476例MetS患者（病例组）和476例年龄和性别匹配的对照组。
病例组的平均天冬氨酸转氨酶（AST）和丙氨酸转氨酶（ALT）水平高于对照组（分别为20.59对19.99，p = 0.339；分别为24.64对20.16，p < 0.001）。ALT≥40的人群患MetS、高甘油三酯和空腹血糖（FBG）的几率显著更高（分别为1.63、2.35和2.02）。AST≥40的人群患MetS的几率比AST水平正常的人群高1.45倍（p > 0.05）。
本研究表明肝酶与MetS及其某些组分之间存在关联。肝酶，尤其是ALT，可作为高危人群中MetS的早期指标。
